Better Medicine for Children Act

The Better Medicine for Children Act (S. 1301) aims to improve the safety and effectiveness of medications used to treat children by encouraging more pediatric-specific clinical research. The bill would provide pharmaceutical companies with extended market exclusivity for drugs in exchange for conducting these studies, while also establishing a federal process to fund research for older drugs that no longer have patent protection. Additionally, it would create an Office of Pediatric Therapeutics within the FDA to coordinate these efforts and ensure that drug labeling includes accurate dosage and safety information specifically for infants and children.